Abstract
Background
Multicentric papillary thyroid carcinoma (PTC) is not unusual in patients with PTC. However, its clinical features concerning cancer recurrence and mortality are not well described.
Methods
A total of 1682 PTC patients at a single institution who underwent total thyroidectomy were retrospectively reviewed; the mean follow-up period was 7.7 ± 0.1 years. Postoperative radioactive iodide ablation for thyroid remnant was performed after surgery for most patients.
Results
Of all the PTC cases reviewed, 337 cases (20.0%) were categorized as multicentric PTC. Compared with patients with unifocal PTC, multicentric PTC patients demonstrated older age, advanced TNM staging, and higher recurrence. A higher recurrence rate for multicentric PTC (20.2%) was observed compared with that for unifocal PTC; 45.8% of multicentric PTC cases with ≥ 5 foci experienced cancer recurrence. Mean tumor size of the largest nodule in patients with multicentric PTC was significantly smaller than that found in unifocal PTC. Patients with multicentric papillary microcarcinoma (≤1 cm) had higher recurrence rate and cancer mortality than those with unifocal papillary microcarcinoma. Of the recurrent multicentric PTC cases, 52.9% were persistent or diagnosed within the first year of thyroidectomy and had a cancer-related mortality of 27.8%. The 5-, 10-, and 20-year survival rates of multicentric PTC patients were 97.7%, 94.4%, and 84.7%, respectively, which were not statistically different from those of unifocal PTC patients.
Conclusions
Multicentric PTC warrant postoperative adjuvant therapy and close surveillance within the first year. Patients with multicentric papillary thyroid microcarcinoma need to be treated as high-risk patients.
Similar content being viewed by others
References
Links TP, van Tol KM, Jager PL, Plukker JT, Piers DA, Boezen HM, et al. Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer. 2005;12:273–80.
Cheema Y, Repplinger D, Elson D, Chen H. Is tumor size the best predictor of outcome for papillary thyroid cancer? Ann Surg Oncol. 2006;13:1524–8.
Low TH, Delbridge L, Sidhu S, Learoyd D, Robinson B, Roach P, et al. Lymph node status influences follow-up thyroglobulin levels in papillary thyroid cancer. Ann Surg Oncol. 2008;15:2827–32.
Giannini R, Ugolini C, Lupi C, Proietti A, Elisei R, Salvatore G, et al. The heterogenous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:3511–6.
Sobin LH, UICC (2002) Wittekind Ch, editor. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002. p. 52–6.
Lin JD, Kuo SF, Chao TC, Hsueh C. Incidental and nonincidental papillary thyroid microcarcinoma. Ann Surg Oncol. 2008;15:2287–92.
Delellis RA, Lloyd RV, Heitx PU, Eng C. Pathology and genetics of tumors of endocrine organs. In: World health organization of tumours. Lyon: IARC; 2004. p. 73–6.
Zhang DD, Zhou XH, Freeman DH, Freeman JL. A non-parametric method for the comparison of partial areas under ROC curves and its application to large health care data sets. Stat Med. 2002;21:701–15.
Simonowitz D, Thomsen S, Moossa AR, Block GE. The treatment of incidental papillary thyroid cancer. Arch Surg. 1976;111:477–83.
Miyaki M, Iijima T, Ishii R, Hishima T, Mori T, Yoshinaga K, et al. Molecular evidence for multicentric development of thyroid carcinomas in patients with familial adenomatous polyposis. Am J Pathol. 2000;157:1825–7.
Gerfo PL, Chabot J, Gazetas P. The intraoperative incidence of detectable bilateral and multicentric disease in papillary cancer of the thyroid. Surgery. 1990;108:958–62.
Kebebew E. Hereditary non-medullary thyroid cancer. World J Surg. 2008;32:678–82.
Stoffer SS, Van Dyke DL, Bach JV, Szpunar W, Weiss L. Familial papillary carcinoma of the thyroid. Am J Med Genet. 1986;25:775–82.
Yamamoto Y, Maeda T, Izumi K, Otsuka H. Occult papillary carcinoma of the thyroid. A study of 408 autopsy cases. Cancer. 1990;65:1173–9.
Aherne ST, Smyth PC, Flavin RJ, Russell SM, Denning KM, Li JH, et al. Geographic mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling. Mol Cancer. 2008;7:89.
Lee X, Gao M, Ji Y, Yu Y, Feng Y, Li Y, et al. Analysis of differential BRAF(V600E) mutation status in high aggressive papillary thyroid microcarcinoma Ann Surg Oncol. 2009;16:240–5.
Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92:4085–90.
Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, et al. BRAF (V600E) mutation and p27 (kip1) expression in papillary carcinomas of the thyroid </=1 cm and their paired lymph node metastases. Cancer. 2007;110:1218–26.
Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol. 2005;63:588–93.
Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch. 2005;446:589–95.
Martinez-Tello FJ, Martinez-Cabruja R, Fernandez-Martin J, Lasso-Oria C, Ballestin-Carcavilla C. Occult carcinoma of the thyroid. A systematic autopsy study from Spain of two series performed with two different methods. Cancer. 1993;71:4022–9.
Furmanchuk AW, Roussak N, Ruchti C. Occult thyroid carcinomas in the region of Minsk, Belarus. An autopsy study of 215 patients. Histopathology. 1993;23:319–25.
Toniato A, Boschin IM, Piotto A, Pelizzo MR, Guolo A, Foletto M, et al. Complications in thyroid surgery for carcinoma: one institution’s surgical experience. World J Surg. 2008;32:572–5.
Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg. 2006;141:489–94.
Frilling A, Görges R, Tecklenborg K, Gassmann P, Bockhorn M, Clausen M, Broelsch CE. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery. 2000;128:1067–74.
Seiboth L, Van Nostrand D, Wartofsky L, Ousman Y, Jonklaas J, Butler C, et al. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid. 2008;18:103–11.
Giovanella L, Ceriani L, Ghelfo A, Keller F. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med. 2005;43:843–7.
Bardet S, Malville E, Rame JP, Babin E, Samama G, De Raucourt D, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol. 2008;158:551–60.
Perrino M, Vannucchi G, Vicentini L, Cantoni G, Dazzi D, Colombo C, et al. Outcome predictors and impact of central node dissection and radiometabolic treatment in papillary thyroid cancers <=2 cm. Endocr Relat Cancer. 2009;16:201–10.
Noguchi S, Yamashita H, Uchino S. Modified radical neck dissection is better than partial dissection of lymph nodes. World J Surg. 2009;33:394–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lin, JD., Chao, TC., Hsueh, C. et al. High Recurrent Rate of Multicentric Papillary Thyroid Carcinoma. Ann Surg Oncol 16, 2609–2616 (2009). https://doi.org/10.1245/s10434-009-0565-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-009-0565-7